Brian Metzger, MD
Infectious Disease · Austin, TXNPI 1538306899
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,355 of the $86,319 with a category attached, or 75.7%. 32 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 34.7% of the total. Reporting peaked in 2023 at $33,011 and has fallen 73.4% since, to $8,784 in 2025. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 730 payments — averaging $118.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$30K
- Cumberland Pharmaceuticals, Inc.$23K
- AbbVie$12K
- Melinta Therapeutics, LLC$9K
- Gilead$4K
- Viiv Healthcare Company$3K
- plus $6K from 26 others
Across 69 payments — averaging $3373.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$113K
- Pfizer$65K
- ADMA Biomanufacturing LLC$54K
What the payments were for
- Consulting fees$2,1002%
- Speaking & faculty fees$65,35576%
- Travel & lodging$9441%
- Food & beverage$16,23519%
- Education$1,6852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 61 | $29,945 |
| Cumberland Pharmaceuticals, Inc. | 57 | $22,625 |
| AbbVie(2 entities) | 62 | $11,888 |
| Melinta Therapeutics, LLC | 21 | $8,656 |
| Gilead | 174 | $3,855 |
| Viiv Healthcare Company | 119 | $3,433 |
| Merck | 57 | $1,764 |
| Octapharma USA, Inc. | 20 | $602 |
| Astellas Pharma US Inc | 16 | $528 |
| Insmed, Inc. | 23 | $516 |
| La Jolla Pharmaceutical Company | 12 | $431 |
| Johnson & Johnson(2 entities) | 22 | $381 |
| Paratek Pharmaceuticals, Inc. | 19 | $341 |
| Shionogi Inc | 15 | $266 |
| EMD Serono, Inc. | 8 | $175 |
| Mayne Pharma Commercial LLC | 7 | $149 |
| Pfizer | 7 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| Theratechnologies Inc. | 5 | $86 |
| Aimmune Therapeutics, Inc. | 3 | $76 |
| Napo Pharmaceuticals Inc | 3 | $75 |
| ADMA Biomanufacturing LLC | 2 | $42 |
| Dynavax Technologies Corporation | 2 | $37 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $36 |
| Vyera Pharmaceuticals, LLC | 2 | $33 |
| CSL Behring | 1 | $33 |
| Janssen Products, LP | 1 | $30 |
| Invivyd Inc | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Romark Laboratories, LC | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,319 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 62 | $249,840 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $70,333 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $57,068 |
| JulucaDolutegravir/Rilpivirine | 11 | $38,018 |
| Vancomycin Hcl | 31 | $3,332 |
| Cefazolin Sodium | 34 | $2,107 |
| CeftriaxoneCeftriaxone Sodium | 32 | $1,498 |
| Cephalexin | 46 | $1,073 |
| ValacyclovirValacyclovir Hcl | 12 | $477 |
| Fluconazole | 11 | $413 |
| Doxycycline Hyclate | 18 | $254 |
| Metronidazole | 13 | $192 |
| Amoxicillin | 12 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $3,855 | $249,84062 claims |
| Viiv Healthcare CompanyDovato, Juluca | $3,433 | $108,35033 claims |
| Janssen Products, LPSymtuza | $30 | $57,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Austin
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
- Roger BedimoDallas$269K
- Miguel Sierra-HoffmanVictoria$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.